XNYS
JNJ
Market cap616bUSD
Jul 22, Last price
255.63USD
1D
2.00%
1Q
10.83%
Jan 2017
121.88%
Name
Johnson & Johnson
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Johnson & Johnson functions as a global healthcare enterprise, involved in the research, development, manufacturing, and commercialization of a wide spectrum of health-related products. Its activities are organized across three principal divisions: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment provides an extensive range of goods, encompassing baby care items under brands like JOHNSON'S and AVEENO Baby, oral hygiene products such as LISTERINE, and skin/beauty solutions from AVEENO, NEUTROGENA, and OGX. It also offers over-the-counter medications for various ailments, including pain relief (TYLENOL, MOTRIN IB), cold, flu, and allergy symptoms (SUDAFED, BENADRYL, ZYRTEC), smoking cessation aids (NICORETTE), and acid reflux treatments (PEPCID). Additionally, this division includes women's health products like STAYFREE and o.b., wound care essentials such as BAND-AID adhesive bandages, and NEOSPORIN for first aid. The Pharmaceutical segment is dedicated to developing therapies within significant therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic disorders. The Medical Devices segment delivers sophisticated solutions for cardiovascular conditions, including electrophysiology and neurovascular care for strokes. It also provides orthopaedic products supporting hips, knees, trauma, spine, and sports-related needs, alongside advanced and general surgical solutions focusing on breast aesthetics and ear, nose, and throat procedures. Furthermore, this segment offers ophthalmic products, notably ACUVUE brand disposable contact lenses and technologies for cataract and laser refractive surgery. The company distributes its products through diverse channels, reaching the general public via retail outlets and distributors, and directly supplying wholesalers, hospitals, and healthcare professionals for prescription-based use. Johnson & Johnson was established in 1886 and maintains its headquarters in New Brunswick, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑00 | 2021‑00 | 2019‑12 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2017‑00 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||